Beijing Minkang Baicao Medicine Technology Co.,Ltd.

This study aimed to investigate the pharmacokinetic characteristics of single fasting and postprandial oral administration of Asartan Potassium Tablets (80 mg), which is owned by Beijing Minkang Baicao Pharmaceutical Technology Co., Ltd. and produced by Chifeng Sailintai Pharmaceutical Co., Ltd.; using Asartan Potassium Tablets (Edabib®, 80 mg), which is licensed by Takeda Pharma A/S and produced by Takeda Ireland Ltd., as the reference preparation, to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations and evaluate the bioequivalence of the two preparations in humans.

Main study purpose This study uses the certified pediatric faropenem sodium granules of Beijing Minkang Baicao Pharmaceutical Technology Co., Ltd., specification: 0.05g (calculated as C12H15NO5S) as the test preparation, and the certified pediatric faropenem sodium granules (trade name: Feromu) of Maruho Co., Ltd., specification: 0.05g (calculated as C12H15NO5S) as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation under postprandial conditions. Secondary study purpose Observe the safety of the test preparation and the reference preparation in healthy subjects.

Main purpose This study uses Bilastine Tablets (specification: 20 mg) produced by Chifeng Sailintai Pharmaceutical Co., Ltd. commissioned by Beijing Minkang Baicao Pharmaceutical Technology Co., Ltd. as the test preparation, and Bilastine Tablets (trade name: Bilaxten®, specification: 20 mg) produced by the original research unit Faes Farma, S.A. as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation under fasting conditions. Secondary purpose Observe the safety of the test preparation and the reference preparation in healthy subjects.